News

The company reported a net loss available to common shareholders of $320.3 million, or $1.05 per diluted share, for the year ended December 31, 2008, compared to a

The company has a number of ready to partner preclinical and early clinical projects focused on improving oral, sublingual and transdermal medication. Orexo will acquire the company for

Shire’s new office will serve as the base for preparations for the future commercialization of its pipeline products in Japan. In his new role, Mr Fujiwara will oversee

This acquisition will broaden the scope of Shire’s attention deficit hyperactivity disorder (ADHD) portfolio and will facilitate immediate access to the European ADHD market as well as provide

Texcel Medical said that, in this role, Mr Smith will oversee all functions at the company, which helps companies around the world by providing the manufacturing infrastructure and

Prior to joining PolyRemedy, Mr Jones served as COO at Reliant Technologies, a medical device company. Previously, Mr Jones was COO at LuMend, an interventional cardiology medical device

The European approval of Valdoxan is based on both short- and long-term results from a large, comprehensive, international development program including almost 6,000 adult patients with depression, said

According to the company, these trials were designed to determine whether there is justification for further clinical development of lacosamide and rotigotine in these indications. The respective studies

The assets to be acquired include the intellectual property relating to the business, other intangibles, inventories and fixed assets. Zoll will, as part of this agreement, assume warranty